Vascular endothelial growth factor‐A as a promising therapeutic target for the management of psoriasis
Open Access
- 12 July 2020
- journal article
- research article
- Published by Wiley in Experimental Dermatology
- Vol. 29 (8) , 687-698
Abstract
Vascular endothelial growth factor‐A (VEGF‐A), the main angiogenic mediator, plays a critical role in the pathogenesis of several inflammatory immune‐mediated diseases, including psoriasis. Even though anti‐angiogenic therapies, such as VEGF inhibitors, are licensed for the treatment of various cancers and eye disease, VEGF‐targeting interventions are not part of current psoriasis therapy. In this viewpoint essay, we argue that the existing preclinical research evidence on the role of VEGF‐A in the pathogenesis of psoriasis as well as clinical observations in patients who have experienced psoriasis remission during oncological anti‐VEGF‐A therapy strongly suggests to systematically explore angiogenesis targeting also in the management of psoriasis. We also point out that some psoriasis therapies decrease circulating levels of VEGF‐A and normalise the psoriasis‐associated vascular pathology in the papillary dermis of plaques of psoriasis and that a subset of patients with constitutionally high levels of VEGF‐A may benefit most from the anti‐angiogenic therapy we advocate here. Given that novel, well‐targeted personalised medicine therapies for the development of psoriasis need to be developed, we explore the hypothesis that VEGF‐A and signalling through its receptors constitute a promising target for therapeutic intervention in the future management of psoriasis.Keywords
Funding Information
- British Skin Foundation
This publication has 100 references indexed in Scilit:
- Double Anti-angiogenic and Anti-inflammatory Protein Valpha Targeting VEGF-A and TNF-α in Retinopathy and PsoriasisJournal of Biological Chemistry, 2011
- Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasisProceedings of the National Academy of Sciences, 2009
- Angiogenesis drives psoriasis pathogenesisInternational Journal of Experimental Pathology, 2009
- Inhibition of Chronic and Acute Skin Inflammation by Treatment with a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase InhibitorThe American Journal of Pathology, 2008
- Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapyJournal of the American Academy of Dermatology, 2006
- Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesisExperimental Cell Research, 2006
- Novel Function for Vascular Endothelial Growth Factor Receptor-1 on Epidermal KeratinocytesThe American Journal of Pathology, 2005
- Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitroAngiogenesis, 2004
- Single-Nucleotide Polymorphisms of Vascular Endothelial Growth Factor in Psoriasis of Early OnsetJournal of Investigative Dermatology, 2004
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993